Imaging Evaluation of the Therapeutic Response of Breast Cancer Bone Metastasis (EMOS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02900118|
Recruitment Status : Completed
First Posted : September 14, 2016
Last Update Posted : September 14, 2016
Breast cancers are among the cancers that metastasize the most to the skeleton. The appearance of bone metastasis, whether they are initials or during a relapse, is a turning point of the disease, due to the additional morbidity they imply (pain, pathologic fractures, hypercalcaemia, neurological compression, etc.). A specific treatment of these metastasis is often undertaken, usually a chemotherapy or hormone therapy. It is important to evaluate the efficacy of this treatment in order to know whether to continue or change it depending on the response observed. But there is no consensus at this time on paraclinical examinations enabling this monitoring. Also, if some criteria for assessing bone metastasis in imaging and nuclear medicine (MDA, PERCIST, EORTC) have been published in the literature, none is formally validated and evaluation in routine practice remains subjective.
The main objective of our study is to determine if the PET-CT and the whole-body MRI are in agreement on the status of bone metastasis (stability, progression, partial response, complete response).
|Condition or disease|
The oncologist includes patients responding to criteria and not opposing the collection of their data. He submits a request for whole-body MRI and PET-CT to the Medical Imaging and Nuclear Medicine departments of the Oscar Lambret Centre. If the patient has benefited within the previous 15 days of any of these examinations, it is not performed again : it will serve as an initial examination. Following these examinations, the oncologist completes the reading grid. A clinical examination and a questioning with the main stages of the disease is performed and data are reported in the dedicated sheet. A prescription of tumor markers and of bone remodeling is performed (in the absence of recent results), and the results are reported on the same sheet.
After 3 cycles (of intravenous chemotherapy) or 3 months of hormone therapy, the oncologist submits a new request for whole-body MRI and PET-CT. The MRI and PET-CT should conclude to a status : progression, stability, partial response, complete response. The reading grid is completed again. MDA criteria (MRI and PET-CT), PERCIST and EORTC (PET-CT only) are determined. Target lesions (1 to 3) are defined for each examination and a measure of the ADC and the SUV is performed for each lesion on the initial and follow-up examinations.
After these examinations, the patient is reviewed by his oncologist for a new clinical examination, the announcement of the status of bone metastasis and the possible adaptation of the treatment.
|Study Type :||Observational|
|Actual Enrollment :||28 participants|
|Official Title:||Imaging Evaluation of the Therapeutic Response of Breast Cancer Bone Metastasis|
|Study Start Date :||August 2012|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||October 2013|
Patients with breast cancer bone metastasis at the initial diagnosis.
Patients with breast cancer bone metastasis in a metastatic bone relapse.
Patients with breast cancer bone metastasis with a progression of bone metastasis.
- Evaluation of the therapeutic response. [ Time Frame: Cycle 3 (each cycle is 28 days) ]
- Evaluation of the concordance of the Apparent Diffusion Coefficient (ADC) and the Standardized Uptake Value (SUV). [ Time Frame: At baseline ]
- Evaluation of the concordance of the Apparent Diffusion Coefficient (ADC) and the Standardized Uptake Value (SUV). [ Time Frame: Cycle 3 (each cycle is 28 days) ]
- Evaluation of the consistency in the detection of lesions. [ Time Frame: Cycle 3 (each cycle is 28 days) ]
- Evaluation of the criteria PERCIST (PET Response Criteria in Solid Tumors) [ Time Frame: Cycle 3 (each cycle is 28 days) ]
- Evaluation of the criteria MDA (Minimal Disease Activity) [ Time Frame: Cycle 3 (each cycle is 28 days) ]
- Evaluation of the criteria EORTC (European Organisation for Research and Treatment of Cancer). [ Time Frame: Cycle 3 (each cycle is 28 days) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02900118
|Centre Oscar Lambret|
|Lille, France, 59020|
|Principal Investigator:||Armelle RENAUD, MD||Centre Oscar Lambret|